

GLOBAL PHARMATECH INC.
Flat/RM 705, 7/F, Fa Yuen Commercial Building
No. 75, Fa Yuen Street, Mong Kok, KL, Hong Kong

Annual Report

For the period ending December 31, 2025 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

415,211,785 as of December 31, 2025

405,211,785 as of December 31, 2024

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Formerly=Autocarbon.com Inc. until 2-05

Current State and Date of Incorporation or Registration: Delaware – June 26, 2001

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

Flat/RM 705, 7/F, Fa Yuen Commercial Building
No. 75, Fa Yuen Street, Mong Kok, KL, Hong Kong

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Pacific Stock Transfer Company
Phone: 702-361-3033
Email: Luke <Luke@pacificstocktransfer.com>
Address: 6725 Via Austi Pkwy., Ste. 300
Las Vegas, NV 89119

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>GBLP</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>37945N109</u>	
Par or stated value:	<u>.0001</u>	
Total shares authorized:	<u>700,000,000</u>	as of date: <u>December 31, 2025</u>
Total shares outstanding:	<u>415,211,785</u>	as of date: <u>December 31, 2025</u>
Total number of shareholders of record:	<u>141</u>	as of date: <u>December 31, 2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of securities outstanding:	<u>Preferred A</u>	
Par or stated value:	<u>.0001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>December 31, 2025</u>
Total shares outstanding:	<u>9,750,000</u>	as of date: <u>December 31, 2025</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>December 31, 2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. **For common equity, describe any dividend, voting and preemption rights.**

No dividend, each common share has one vote, no preemption rights

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

No Dividend. The Convertible Preferred Stock - One Preferred Share for One Thousand Voting Right; One Preferred Share can be converted into One Thousand Common Shares

3. **Describe any other material rights of common or preferred stockholders.**

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> :			*Right-click the rows below and select "Insert" to add rows as needed.						
Date <u>12.31.22</u>	Common: <u>282,851,785</u>	Preferred: <u>9,750,000</u>							
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>05.26.2021</u>	<u>New</u>	<u>10,000,000</u>	<u>Preferred</u>	<u>0.0001</u>	<u>No</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	
<u>12/03/2021</u> *	<u>New / Preferred to Common conversion</u>	<u>250,000,000</u>	<u>Common</u>	<u>0.0001</u>	<u>No</u>	<u>Yong Sheng</u>	<u>Preferred Share conversion</u>	<u>Restricted</u>	
<u>12/27/2021</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.0235</u>	<u>Yes</u>	<u>Juan Peng</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/27/2021</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.0235</u>	<u>Yes</u>	<u>Haibo Li</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>

<u>12/27/2021</u>	<u>New</u>	<u>300,000</u>	<u>Common</u>	<u>0.0235</u>	<u>Yes</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>08/29/2022</u>	<u>New</u>	<u>1,200,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Haibo Li</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>08/29/2022</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Dong Ming Zhao</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>08/29/2022</u>	<u>New</u>	<u>500,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>1,500.00</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Haibo Li</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Dong Ming Zhao</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>1,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Yinchen Liu</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>12/26/2022</u>	<u>New</u>	<u>300,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Caren Currier</u>	<u>Services</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>85,200,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Meisheng Liao</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>15,160,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Ruiqi Sheng</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>5,400,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Guanghua Wen</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>4,600,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Chi Zhang</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>02/21/2023</u>	<u>New</u>	<u>2,000,000</u>	<u>Common</u>	<u>0.025</u>	<u>Yes</u>	<u>Jianhua Zhu</u>	<u>Exchange</u>	<u>Restricted</u>	<u>Rule 144</u>
<u>10/14/2024</u>	<u>New</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Juan Peng</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>Rule 144</u>
<u>01/10/2025</u>	<u>New</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>Xiyu Zhang</u>	<u>Debt Conversion</u>	<u>Restricted</u>	<u>Rule 144</u>
Shares Outstanding on Date of This Report:									
Ending Balance:									
Date <u>12.31.25</u> Common: <u>415,211,785</u>									
Preferred: <u>9,750,000</u>									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

- Yong Sheng converted 250,000 Preferred Shares to 250,000,000 common shares

<u>8.30.21</u>	<u>Transfer</u>	<u>10,000,000</u>	<u>Preferred</u>	<u>.0001</u>	<u>No</u>	<u>Yong Sheng</u>	<u>Transfer from Caren Currier</u>	<u>Restricted</u>
<u>12/03/2021</u>	<u>Transfer</u>	<u>9,750,000</u>	<u>Preferred</u>	<u>0.0001</u>	<u>No</u>	<u>Kingwood International Holding LTD Yong Sheng</u>	<u>Transfer</u>	<u>Restricted</u>

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

<u>Date of Note Issuance</u>	<u>Principal Amount at Issuance (\$)</u>	<u>Outstanding Balance (\$)</u> <u>(include accrued interest)</u>	<u>Maturity Date</u>	<u>Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)</u>	<u># Shares Converted to Date</u>	<u># of Potential Shares to be Issued Upon Conversion⁵</u>	<u>Name of Noteholder (entities must have individual with voting / investment control disclosed).</u>	<u>Reason for Issuance (e.g., Loan, Services, etc.)</u>
<u>7.1.21</u>	<u>40,000</u>	<u>40,000</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001. Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;</u>	<u>0</u>	<u>40,000,000</u>	<u>Haizhen Liao</u> <u>The convertible note was assigned to Haizhen Liao from Kingstone Financial Inc on October 18, 2022</u>	<u>Loan</u>
<u>11/15/22</u>	<u>10,000</u>	<u>10,000</u>	<u>On Demand</u>	<u>Company's Common Stock based on a conversion price of \$0.001. Whereas the Company and Note Holder Intend to limit the Note</u>	<u>0</u>	<u>10,000,000</u>	<u>Juan Peng</u>	<u>Loan</u>

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

				Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;				
<u>21/07/23</u>	<u>10,000</u>	<u>10,000</u>	<u>On Demand</u>	Company's Common Stock based on a conversion price of \$0.001 Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;	0	<u>10,000,000</u>	<u>Haizhen Liao</u>	<u>Loan</u>
<u>15/08/24</u>	<u>10,000</u>	<u>10,000</u>	<u>On Demand</u>	Company's Common Stock based on a conversion price of \$0.001 Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;	0	<u>10,000,000</u>	<u>Haizhen Liao</u>	<u>Loan</u>
<u>16/07/25</u>	<u>15,000</u>	<u>15,000</u>	<u>15/07/26</u>	Company's Common Stock based on a conversion price of \$0.010 Whereas the Company and Note Holder Intend to limit the Note Holder upon any conversion to holding in excess 9.99% of the total issued and outstanding shares of common stock of the Company;	0	<u>1,500,000</u>	<u>Haizhen Liao</u>	<u>Loan</u>

Any additional material details, including footnotes to the table are below:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Global Pharmatech, Inc.(GBLP) incorporated a wholly owned subsidiary - Vitalia Health Inc. based in Toronto, Canada on April 29, 2023, and the subsidiary will focus on manufacturing and marketing of dietary supplements focus on anti-aging, anti-diebitics, immune enhancement, energy booster, and weight management as well as distribution of botanical extracts/herbal extracts in Canada.

Global Pharmatech, Inc.(GBLP) acquired 100% ownership of Botaniex, Inc. through the share exchange agreement executed on December 18, 2022, Botaniex, Inc. is a Delaware Corporation incorporated in 2005, and it has been operating through its 100% owned subsidiary of Changsha Botaniex, Inc. in China since 2005.

Botaniex is a market-oriented supplier & manufacturer of natural ingredients (botanical extracts/herbal extracts and herbal formulations) for the Industries of Dietary Supplements, Functional Foods, Functional Beverages, Cosmetics and Pharmaceuticals. By co-operating with the strategic partners like universities, Botaniex's R&D team is dedicated to development of the new natural ingredients and the herbal formulations focusing on men's health and women's health. In addition, both the advanced equipment and sophisticated technology are employed to produce the high quality and customized botanical extracts and herbal formula. We also provide customers with value added services such as Private Labels, Contract Manufacturing, and etc.

Currently Botaniex, Inc. owns the patents as follows:

- A Technology to Extract Sea Buckthorn Oil by Enzyme and CO2 (Super-Critical Fluid Extraction (Patent Number: ZL 2014-1-0009702.6);
- A Technology to Extract L-Theanine from Green Tea (Patent Number: ZL 2015-1-0578407.7);
- A Technology to Extract Actinidin from Kiwi Fruit (Patent Number: ZL 2013-1-0731769.6);

Furthermore, Botanies owns the following Trademarks

- EJACON – a brand used for men's health products (Trademark#: 4998788)
- Slimmer-Trimmer – a brand used for weight management; (Trademark#: 4998779)
- Twin-Peaks – a brand used for women's beauty (Trademark#: 5469534)

B. List any subsidiaries, parent company, or affiliated companies.

Vitalia Health Inc. based in Toronto, Canada, a wholly owned subsidiary of Global Pharmatech, Inc. Changsha Botaniex, Inc. is a subsidiary of 100% owned by Botaniex, Inc. Botaniex, Inc. registered a 100% owned subsidiary in Florida, but has no operations yet Global Pharmatech, Inc.(GBLP) is the parent company of all the above-mentioned companies/subsidiaries

C. Describe the issuers' principal products or services.

Botaniex, In., as a wholly owned subsidiary of Global Pharmatech, Inc. provides the three categories of products and services:

- Herbal Extracts including Tea Extracts, Mushroom Extracts, Ginseng Extracts, Kiwi Fruit Extracts, Ginger Extracts, and etc;
- Herbal Formulation – Weight Loss, Male Enhancement, Immunity Enhancement, and etc'
- Value Added Services – Private Label/OEM

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

Changsha Botaniex, Inc. has owned a 4,000 square feet office, located at 1-403, Building A4, Lu-Valley Compark, 27 Wenxuan Road, Lu-Valley High-Tech Development District, Changsha, China 410205

Vitalia Health Inc. has leased an office located in 205 Placer Ct. Unit 201, Toronto, Canada M2H 0A9

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
<u>Yong Sheng</u>	<u>5%</u> <u>Director</u>	<u>Chenzhou, Hunan Province, China</u>	<u>250,000,000</u>	<u>Common</u>	<u>60.21%</u>
<u>Kingwood International Holding Limited</u> <u>Yong Sheng</u>	<u>5%</u>	<u>Hong Kong, China</u>	<u>9,750,000</u>	<u>Preferred</u>	<u>100%</u>
<u>Meisheng Liao**</u>	<u>5%</u> <u>CEO & President</u>	<u>Mississauga, Ontario, Canada</u>	<u>85,200,000</u>	<u>Common</u>	<u>20.52%</u>

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

- 1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

- 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

- 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

- 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a “yes” answer to part 3 above; or

None

- 5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person’s involvement in any type of business or securities activities.

None

- 6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name:
Address 1:
Address 2:
Phone:
Email:

Accountant or Auditor

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Melson Liao**
Title: **President / CEO**
Relationship to Issuer: **President / CEO**

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Caren Currier**
Title: **Consultant**
Relationship to Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements:⁶ **25 years of accounting history.**

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet.
- Statement of Income.
- Statement of Cash Flows.
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Melson Liao certify that:

1. I have reviewed this Disclosure Statement for GLOBAL PHARMATECH INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 11, 2026 [Date]

/s/Melson Liao [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Melson Liao certify that:

1. I have reviewed this Disclosure Statement for GLOBAL PHARMATECH INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 11, 2026 [Date]

/s/Melson Liao [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

GLOBAL PHARMATECH INC.
Balance Sheet Prev Year Comparison
As of December 31, 2025

	<u>Dec 31, 25</u>	<u>Dec 31, 24</u>
ASSETS		
Current Assets		
Checking/Savings		
Botaniex Cash	105,401.73	19,938.08
Rotal Bank of Canada - 400-3414	146.99	37.50
Royal Bank of Canada - 103-409-	4,770.49	5,490.49
US Bank	5,603.92	4,266.68
Total Checking/Savings	<u>115,923.13</u>	<u>29,732.75</u>
Other Current Assets		
Accounts Receivable	329,701.82	328,296.55
Advance to Suppliers	23,489.46	9,401.00
Inventory	6,951.90	18,502.36
Other Current Assets	65,794.10	665.97
Other Receivables	69,737.39	0.00
Total Other Current Assets	<u>495,674.67</u>	<u>356,865.88</u>
Total Current Assets	<u>611,597.80</u>	<u>386,598.63</u>
Fixed Assets		
Accumulated Depreciation	-46,299.28	-39,873.74
Fixed Assets	123,927.97	123,927.97
Total Fixed Assets	<u>77,628.69</u>	<u>84,054.23</u>
Other Assets		
Goodwill	82,897.26	82,897.26
Intangible Assets	17,552.70	17,485.21
Long Term Equity Investment	180,900.00	180,900.00
Total Other Assets	<u>281,349.96</u>	<u>281,282.47</u>
TOTAL ASSETS	<u>970,576.45</u>	<u>751,935.33</u>
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities		
Other Current Liabilities		
Accts Payable Botaniex	436,686.87	429,696.23
advances from customers	381,433.39	181,403.58
Convertible Notes Payable	20,000.00	0.00
Due to M Membrado	15,740.00	740.00
Loan - Melson	10,575.33	10,411.84
Loan - Ruiqui Sheng	20,000.00	20,000.00
Notes Payable - Kingstone	40,000.00	50,000.00
Other Payables & Accruals	173,267.37	180,017.04
Payroll Liabilities	337.24	0.00
Total Other Current Liabilities	<u>1,098,040.20</u>	<u>872,268.69</u>
Total Current Liabilities	<u>1,098,040.20</u>	<u>872,268.69</u>
Total Liabilities	<u>1,098,040.20</u>	<u>872,268.69</u>

GLOBAL PHARMATECH INC.
Balance Sheet Prev Year Comparison
As of December 31, 2025

	<u>Dec 31, 25</u>	<u>Dec 31, 24</u>
Equity		
Additional Paid in Capital	11,870,167.32	11,939,126.42
Common Stock	41,521.00	40,521.00
Common Stock - Botaniex	180,000.00	112,360.00
FOREX	1,713.69	21,036.36
Preferred Stock	9,750.00	9,750.00
Retained Earnings	-11,700,707.17	-11,632,979.14
Retained Earnings - Botaniex	-537,419.97	-537,419.97
Subscription Receivable	-5,000.00	-5,000.00
Net Income	12,511.38	-67,728.03
Total Equity	<u>-127,463.75</u>	<u>-120,333.36</u>
TOTAL LIABILITIES & EQUITY	<u>970,576.45</u>	<u>751,935.33</u>

GLOBAL PHARMATECH INC.
Profit & Loss Prev Year Comparison
October through December 2025

	<u>Oct - Dec 25</u>	<u>Oct - Dec 24</u>
Ordinary Income/Expense		
Income		
Sales	165,431.00	25,934.22
Total Income	<u>165,431.00</u>	<u>25,934.22</u>
Cost of Goods Sold		
Cost of Goods Sold	118,378.71	23,936.26
Total COGS	<u>118,378.71</u>	<u>23,936.26</u>
Gross Profit	47,052.29	1,997.96
Expense		
Bank Service Charges	80.84	191.00
Business and Sales Tax	896.54	791.70
Computer and Internet Expenses	56.50	1,302.78
Depreciation Expense	1,851.55	7,214.36
Office Supplies	15,020.80	5,015.42
Professional Fees	250.00	875.00
Rent Expense	0.00	169.50
Selling Expenses	11,287.02	8,893.51
Transfer Agent Fees	507.00	2,313.24
Total Expense	<u>29,950.25</u>	<u>26,766.51</u>
Net Ordinary Income	17,102.04	-24,768.55
Other Income/Expense		
Other Income		
Income on Exchange	724.76	80.03
Interest Income	6.60	0.00
Total Other Income	<u>731.36</u>	<u>80.03</u>
Other Expense		
Penalty	0.00	28.18
Total Other Expense	<u>0.00</u>	<u>28.18</u>
Net Other Income	731.36	51.85
Net Income	<u><u>17,833.40</u></u>	<u><u>-24,716.70</u></u>

GLOBAL PHARMATECH INC.
Profit & Loss Prev Year Comparison
January through December 2025

	<u>Jan - Dec 25</u>	<u>Jan - Dec 24</u>
Ordinary Income/Expense		
Income		
Sales	358,314.95	310,895.90
Total Income	<u>358,314.95</u>	<u>310,895.90</u>
Cost of Goods Sold		
Cost of Goods Sold	245,596.92	269,026.09
Total COGS	<u>245,596.92</u>	<u>269,026.09</u>
Gross Profit	112,718.03	41,869.81
Expense		
Bank Service Charges	308.85	598.87
Business and Sales Tax	3,964.23	1,641.60
Computer and Internet Expenses	169.50	1,472.28
Depreciation Expense	5,177.29	7,214.36
Legal Fees	0.00	1,000.00
Membership Fees	0.00	950.00
Office Supplies	37,672.62	27,004.37
OTC Fees	7,500.00	5,940.00
Professional Fees	2,484.42	1,900.00
Rent Expense	318.50	169.50
Selling Expenses	49,935.66	56,962.00
Transfer Agent Fees	4,248.76	5,431.32
Total Expense	<u>111,779.83</u>	<u>110,284.30</u>
Net Ordinary Income	938.20	-68,414.49
Other Income/Expense		
Other Income		
Debt Forgiveness	9,000.00	0.00
Income on Exchange	1,345.43	709.87
Interest Income	1,227.75	7.77
Total Other Income	<u>11,573.18</u>	<u>717.64</u>
Other Expense		
Ask My Accountant	0.00	3.00
Penalty	0.00	28.18
Total Other Expense	<u>0.00</u>	<u>31.18</u>
Net Other Income	11,573.18	686.46
Net Income	<u><u>12,511.38</u></u>	<u><u>-67,728.03</u></u>

GLOBAL PHARMATECH INC.
Statement of Cash Flows
October through December 2025

	<u>Oct - Dec 25</u>	<u>Oct - Dec 24</u>
OPERATING ACTIVITIES		
Net Income	17,833.40	-24,716.70
Adjustments to reconcile Net Income to net cash provided by operations:		
Accounts Receivable	-22,070.51	19,431.59
Advance to Suppliers	33,278.35	-2,452.63
Cash & Cash Equivalents	0.00	0.00
Inventory	66.22	478.41
Other Current Assets	-54,350.92	403.78
Other Receivables	0.00	0.00
Related Party Receivable	0.00	0.00
Accounts Payable	0.00	0.00
Accts Payable Botaniex	3,205.99	-2,502.35
advances from customers	81,590.27	9,419.57
Convertible Notes Payable	0.00	0.00
Current Portion-Long Term Debt	0.00	0.00
Due to Caren Currier	0.00	0.00
Due to M Membrado	0.00	740.00
Loan - Melson	0.00	0.00
Loan - Ruiqui Sheng	0.00	-10,000.00
Notes Payable - Kingstone	0.00	0.00
Other Current Liabilities	0.00	0.00
Other Payables & Accruals	80,443.49	-8,002.82
Payroll Liabilities	-20,070.29	0.00
Tax Payable	0.00	0.00
Net cash provided by Operating Activities	<u>119,926.00</u>	<u>-17,201.15</u>
INVESTING ACTIVITIES		
Accumulated Depreciation	1,851.55	7,214.36
Fixed Assets	0.00	0.00
Furniture and Equipment	0.00	0.00
Goodwill	0.00	0.00
Intangible Assets	34.13	486.24
Land, Lease	0.00	0.00
Long Term Equity Investment	0.00	-180,900.00
Property, Plant & Equip	0.00	0.00
Net cash provided by Investing Activities	<u>1,885.68</u>	<u>-173,199.40</u>
FINANCING ACTIVITIES		
Additional Paid in Capital	-68,959.10	209,233.37
Capital Stock	0.00	0.00
Common Stock	0.00	-4,850.00
Common Stock - Botaniex	0.00	0.00
Dividends Paid	0.00	0.00
FOREX	0.00	0.00

GLOBAL PHARMATECH INC.
Statement of Cash Flows
October through December 2025

	<u>Oct - Dec 25</u>	<u>Oct - Dec 24</u>
Minority Interest	0.00	0.00
Opening Balance Equity	0.00	0.00
Preferred Stock	0.00	0.00
Retained Earnings	0.00	0.00
Retained Earnings - Botaniex	0.00	0.00
Subscription Receivable	0.00	0.00
Net cash provided by Financing Activities	<u>-68,959.10</u>	<u>204,383.37</u>
Net cash increase for period	<u>52,852.58</u>	<u>13,982.82</u>
Cash at beginning of period	<u>63,070.55</u>	<u>15,749.93</u>
Cash at end of period	<u><u>115,923.13</u></u>	<u><u>29,732.75</u></u>

GLOBAL PHARMATECH INC.
Statement of Cash Flows
January through December 2025

	<u>Jan - Dec 25</u>	<u>Jan - Dec 24</u>
OPERATING ACTIVITIES		
Net Income	12,511.38	-67,728.03
Adjustments to reconcile Net Income		
to net cash provided by operations:		
Accounts Receivable	-1,405.27	-186,475.79
Advance to Suppliers	-14,088.46	-2,526.50
Cash & Cash Equivalents	0.00	0.00
Inventory	11,550.46	5,213.62
Other Current Assets	-65,128.13	1,013.67
Other Receivables	-69,737.39	0.00
Related Party Receivable	0.00	0.00
Accounts Payable	0.00	0.00
Accts Payable Botaniex	6,990.64	202,292.64
advances from customers	200,029.81	14,667.16
Convertible Notes Payable	20,000.00	0.00
Current Portion-Long Term Debt	0.00	0.00
Due to Caren Currier	0.00	-1,002.70
Due to M Membrado	15,000.00	740.00
Loan - Melson	163.49	10,000.00
Loan - Ruiqui Sheng	0.00	-10,000.00
Notes Payable - Kingstone	-10,000.00	0.00
Other Current Liabilities	0.00	-8,669.64
Other Payables & Accruals	-6,749.67	69,544.07
Payroll Liabilities	337.24	-12,161.35
Tax Payable	0.00	0.00
Net cash provided by Operating Activities	<u>99,474.10</u>	<u>14,907.15</u>
INVESTING ACTIVITIES		
Accumulated Depreciation	6,425.54	21,212.93
Fixed Assets	0.00	0.00
Furniture and Equipment	0.00	0.00
Goodwill	0.00	0.00
Intangible Assets	-67.49	239.97
Land, Lease	0.00	0.00
Long Term Equity Investment	0.00	-180,900.00
Property, Plant & Equip	0.00	0.00
Net cash provided by Investing Activities	<u>6,358.05</u>	<u>-159,447.10</u>
FINANCING ACTIVITIES		
Additional Paid in Capital	-68,959.10	216,761.42
Capital Stock	0.00	0.00
Common Stock	1,000.00	-4,850.00
Common Stock - Botaniex	67,640.00	0.00
Dividends Paid	0.00	0.00
FOREX	-19,322.67	-4,678.33

GLOBAL PHARMATECH INC.
Statement of Cash Flows
January through December 2025

	<u>Jan - Dec 25</u>	<u>Jan - Dec 24</u>
Minority Interest	0.00	0.00
Opening Balance Equity	0.00	0.00
Preferred Stock	0.00	0.00
Retained Earnings	0.00	0.00
Retained Earnings - Botaniex	0.00	-54,197.11
Subscription Receivable	0.00	0.00
Net cash provided by Financing Activities	<u>-19,641.77</u>	<u>153,035.98</u>
Net cash increase for period	86,190.38	8,496.03
Cash at beginning of period	29,732.75	21,236.72
Cash at end of period	<u><u>115,923.13</u></u>	<u><u>29,732.75</u></u>

Global Pharmatech, Inc.
Shareholders' Equity (Deficiency)
(Unaudited)

	Common Stock		Common Stock-Botaniex		Preferred Stock A		Add'l Paid	Forex	Accumulated	Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	in Capital		Deficit	Equity/(Deficit)
Balance December 31, 2023	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,722,365		(12,137,746)	(225,366)
FOREX									16,544	16,544
Shares Issued										-
Net Gain/(loss) for period ended March 31, 2024									(9,780)	(9,780)
Adj for consolidated										8981
Balance March 31, 2024	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,722,365	21,036	(12,130,982)	(209,621)
FOREX										(10,478)
Shares Issued										
Net Gain/(loss) for period ended June 30, 2024							7,528		(32,762)	(25,234)
Adj for consolidated										
Balance June 30, 2024	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,729,893	21,036	(12,163,744)	(245,333)
Retained Earnings Biotanex										
Shares Issued										
Net Gain/(loss) for period ended September 30, 2024									(54,667)	(54,667)
Adj for consolidated										
Balance September 30, 2024	395,211,785	45,371	112,360,000	112,360	9,750,000	9,750	11,729,893	21,036	(12,218,411)	(300,000)
Retained Earnings Biotanex										
Shares Issued	10,000,000	10,000								10,000
Net Gain/(loss) for period ended December 31, 2024							209,233		(24,717)	184,516
Adj for consolidated		(14,850)								(14,850)
Balance December 31, 2024	405,211,785	40,521	112,360,000	112,360	9,750,000	9,750	11,939,126	21,036	(12,243,128)	(120,334)
Retained Earnings Biotanex										
Shares Issued	10,000,000	1,000								1,000
Net Gain/(loss) for period ended March 31, 2025									4,488	4,488
Adj for consolidated - FOREX								49,156		49,156
Balance March 31, 2025	415,211,785	41,521	112,360,000	112,360	9,750,000	9,750	11,939,126	70,192	(12,238,640)	(65,690)
Retained Earnings Biotanex										
Shares Issued										
Net Gain/(loss) for period ended June 30, 2025									3,026	3,026
Adj for consolidated - FOREX								978		978
Balance June 30, 2025	415,211,785	41,521	112,360,000	112,360	9,750,000	9,750	11,939,126	71,170	(12,235,614)	(61,686)
Retained Earnings Biotanex										
Shares Issued			67,640,000	67,640						67,640
Net Gain/(loss) for period ended September 30, 2025									(12,835)	(12,835)
Adj for consolidated - FOREX								(69,456)		(69,456)
Balance September 30, 2025	415,211,785	41,521	180,000,000	180,000	9,750,000	9,750	11,939,126	1,714	(12,248,449)	(76,338)
Retained Earnings Biotanex							(68,959)			(68,959)
Shares Issued										-
Net Gain/(loss) for period ended December 30, 2025									17,833	17,833
Adj for consolidated - FOREX										-
Balance December 30, 2025	415,211,785	41,521	180,000,000	180,000	9,750,000	9,750	11,870,167	1,714	(12,230,616)	(127,464)

GLOBAL PHARMATECH INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For The Period Ended December 31, 2025

NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies followed in the preparation of these financial statements:

Organizational Information: GLOBAL PHARMATECH INC. (the Company) was incorporated in 2001 in the State of Delaware.

Industry Information: Global Pharmatech, Inc. through its subsidiary, Botaniex, Inc, which is a market-oriented supplier & manufacturer of natural ingredients (botanical extracts/herbal extracts and herbal formulations) for the Industries of Dietary Supplements, Functional Foods, Functional Beverages, Cosmetics and Pharmaceuticals. By co-operating with the strategic partners like universities, Botaniex's R&D team is dedicated to development of the new natural ingredients and the herbal formulations focusing on men's health and women's health. In addition, both the advanced equipment and sophisticated technology are employed to produce the high quality and customized botanical extracts and herbal formula. We also provide customers with value added services such as Private Labels, Contract Manufacturing, and etc. Global Pharmatech's operations are currently based in Changsha, China.

Global Pharmatech, Inc.(GBLP) incorporated a wholly owned subsidiary - Vitalia Health Inc. based in Toronto, Canada on April 29, 2023. The subsidiary will focus on manufacturing and marketing of dietary supplements focus on anti-aging, anti-diebitics, immune enhancement, energy booster, and weight management as well as distribution of botanical extracts/herbal extracts in Canada.

Basis of Presentation: The accounting records of the Company are maintained on the accrual basis and the accompanying financial statements are presented on the accrual basis.

Depreciation and Amortization: The cost of property and equipment is depreciated over the estimated useful lives of the related assets using the accelerated recovery periods of the Internal Revenue Service. Purchased software is amortized on the straight-line basis over five years; organization expense and trademarks are amortized on the straight-line method over sixty months.

Accounts Receivable: The accounts receivable arises in the normal course of business of providing services to Customers. Accounts are written-off as they are deemed uncollectible based upon a periodic review of the accounts. At this time the company has no receivables.

Concentration of Credit Risk: Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of bank deposits and trade accounts receivable. The Company has concentrated its credit risk for cash by maintaining deposits in financial institutions within the geographic region of Lincoln, Nebraska, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (FDIC). There is no excess deposit liabilities at this time. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk to cash. Concentrations of credit risk with respect to accounts receivable arise because the Company grants unsecured credit in the form of trade accounts receivable to its customers.

Management Estimations: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the period. Actual results could differ from those estimates. GLOBAL PHARMATECH INC.

Cash and Equivalents: For purposes of reporting cash flows, the Company considers all cash accounts which are not subject to withdrawal restrictions or penalties, and certificates of deposit with original maturities of 90 days or less to be cash or cash equivalents.

Revenue Recognition: Revenues on subscription contracts are recognized monthly over the life of the contract. Amounts that have been invoiced are recorded in accounts receivable and revenue or deferred revenue, depending upon whether the revenue recognition criteria have been met.

Inventory: The Company maintains its inventory on a perpetual basis utilizing the first-in first-out (FIFO) method. There is no inventory at this time.

NOTE 2: GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has minimal working capital and net losses from inception. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required, and ultimately to attain profitability. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3: INCOME TAX

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes. SFAS 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and

liabilities and the tax rates in effect when these differences are expected to reverse. SFAS 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Consequently, because of uncertainty about the Company's ability to realize any future tax benefits from its unused net operating losses, no deferred tax asset relating to those losses has been recorded.

Changsha Botaniex, Inc. the subsidiary of GBLP, has been operating in China, has no tax income tax payable.

NOTE 4: COMMITMENTS

Changsha Botaniex, Inc. owns a 4,000 square feet office, located at 1-403, Building A4, Lu-Valley Compark, 27 Wenxuan Road, Lu-Valley High-Tech Development District, Changsha, China 410205

NOTE 5: NOTE PAYABLE

The company has Five convertible notes to Related Parties. \$40,000.00 dated July 1, 2021 to Kingstone Financial Inc, which was assigned to Haizhen Liao on October 18, 2022 and, and dated November 15, 2022 to Juan Peng, \$10,000. dated on July 21, 2023 to Haizhen Liao. and \$10,000 dated on Aug 15, 2024 to Haizhen Liao,. On July 16, 2025, a new convertible loan of USD\$15,000.00 signed with HaizhenLiao at conversion rate of USD\$0.01 and the maturity date is July 15, 2026.

The first four notes are payable on demand. All five notes, including the one maturing on July 15, 2026, are convertible up to a maximum of 9.99% of the Company's outstanding common shares at a time.

The Note of \$10,000 dated August 1, 2021 to Kingstone Financial Inc. which was assigned to Xiyu Zhang on October 18, 2022, was converted into 10,000,000 commonshares restricted on 01/10/2025.

The Note of \$10,000 dated March 24, 2022 to Juan Peng, was converted into 10,000,000 unrestricted common shares on 10/14/2024

There is no interest accrued on these Notes.

In June, 2023, GBLP's subsidray, Vitalia Health Inc. got a loan of CAD10,000 with 10% annual interst from Ruiqi Sheng.

NOTE 6: CONSOLIDATION INFORMATION

The financials provided are consolidated financials with the subsidiaries.

NOTE 7: SHAREHOLDER NOTES PAYABLE

These notes are listed above as they are also related parties.

NOTE 8: LITIGATION

None